TrialAdvances in therapy2022

Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial.

Jingxin Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.